Holen Sie sich die Stockscreener-App
2.36
4.07%
-0.10
Handel nachbörslich:
2.36
Schlusskurs vom Vortag:
$2.46
Offen:
$2.47
24-Stunden-Volumen:
395.87K
Relative Volume:
0.22
Marktkapitalisierung:
$258.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-299.80M
KGV:
-0.831
EPS:
-2.84
Netto-Cashflow:
$-217.49M
1W Leistung:
-8.17%
1M Leistung:
+8.51%
6M Leistung:
-60.00%
1J Leistung:
-51.64%
1-Tages-Spanne:
$2.35
$2.49
1-Wochen-Bereich:
$2.34
$2.635
52-Wochen-Spanne:
$1.845
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
Firmenname
Acelyrin Inc
Sektor
Branche
Telefon
805-456-4393
Adresse
4149 LIBERTY CANYON RD., AGOURA HILLS
Vergleichen Sie SLRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
2.36 | 258.82M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-09-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-30 | Eingeleitet | Jefferies | Buy |
| 2023-05-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-05-30 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-30 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Acelyrin Inc Aktie (SLRN) Neueste Nachrichten
INVESTOR ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
ACELYRIN Encourages Stockholders to Support Merger with Alumis Inc. Following ISS Recommendation - Nasdaq
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the ... - Eagle-Tribune
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - Yahoo Finance
Acelyrin Shareholder Notice - Newsfile
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Acelyrin urges stockholders to vote for proposed merger with Alumis - Yahoo Finance
ACELYRIN urges stockholders to approve Alumis merger - Investing.com
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - The Manila Times
ACELYRIN, Inc. Urges Stockholders to Vote in Favor of Proposed Merger with Alumis Inc. Ahead of May 13, 2025 Meeting - Nasdaq
ACELYRIN Board Makes Final Push for Alumis Merger: 48% Ownership Deal at Stake in Critical May Vote - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition - TipRanks
Acelyrin (SLRN) Faces Shareholder Opposition to Alumis Merger - GuruFocus
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis - MSN
Acelyrin stock gains as Trium rebuffs M&A deal (SLRN:NASDAQ) - Seeking Alpha
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - ADVFN
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
Alumis, ACELYRIN amend proposed merger pact - MSN
Alumis And Acelyrin Announce Amended Merger Agreement - marketscreener.com
Alumis Raises Share Consideration for Acelyrin Acquisition - marketscreener.com
ACELYRIN, INC. Amends Merger Agreement with Alumis - TipRanks
ACELYRIN and Alumis Announce Revised Merger Agreement Enhancing Stockholder Ownership and Value - Nasdaq
Alumis and ACELYRIN Announce Amended Merger Agreement - The Manila Times
Alumis Secures Major Immunology Merger: $737M Cash Runway Stretches to 2027, 62% Shareholders Back Deal - Stock Titan
Wheat Pushing Higher Ahead of Export Sales Release - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders - The Malaysian Reserve
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
Best Quantum Computing Stocks to Watch in 2025 - The Globe and Mail
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - TradingView
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
Indo-Asian News Service - Indo-Asian News Service (IANS)
Finanzdaten der Acelyrin Inc-Aktie (SLRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):